The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
Open accessAbstract
Nucleic acid aptamers are a novel class of drugs that can be selected to inhibit targets of interest, including protein-protein interactions.1 Pegnivacogin is a 2′-fluoropyrimidine–modified RNA aptamer that inhibits coagulation factor IXa, coupled to an approximately 40-kDa branched molecule of methoxypolyethylene glycol (mPEG), to increase its concentration and half-life in plasma.2 During the RADAR3 phase 2b clinical trial in patients with acute coronary syndrome, allergic reactions occurred within minutes of a first dose of pegnivacogin in 3 of 640 patients (Table I).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
Aptamers: An Emerging Class of Therapeutics
Nimjee, S. M., Rusconi, C. P., & Sullenger, B. A. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062904.144915 · Cited by 937
Self-citationSymposium on the Definition and Management of Anaphylaxis: Summary report
Sampson, H. A., Muñoz-Furlong, A., Bock, S. A., Schmitt, C., Bass, R., Chowdhury, B. A., Decker, W. W., Furlong, T. J., Galli, S. J., Golden, D. B., et al. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.009 · Cited by 641
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Hershfield, M. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Jaggers, D. A., & Sundy, J. S. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4500 · Cited by 266
Self-citationLipsky, P. E., Calabrese, L. H., Kavanaugh, A., Sundy, J. S., Wright, D., Wolfson, M., & Becker, M. A. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4497 · Cited by 266
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
Self-citationAntisense Drug Technology: Principles, Strategies, and Applications, Second Edition
(2007) · CRC Press eBooks · doi:10.1201/9780849387951 · Cited by 181
Longo, N., Harding, C. O., Burton, B. K., Grange, D. K., Vockley, J., Wasserstein, M., Rice, G. M., Dorenbaum, A., Neuenburg, J. K., Musson, D. G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61841-3 · Cited by 167
Cited by
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Kozma, G. T., Shimizu, T., Ishida, T., & Szebeni, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.024 · Cited by 696
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
Harnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
Nimjee, S. M., White, R. R., Becker, R. C., & Sullenger, B. A. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104558 · Cited by 607
Self-citationChen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., Bawab, A. A., & Ismail, S. I. (2019) · Molecules · doi:10.3390/molecules25010003 · Cited by 415
Yang, Q., Jacobs, T. M., McCallen, J. D., Moore, D. T., Huckaby, J. T., Edelstein, J. N., & Lai, S. K. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03437 · Cited by 370
Aptamers in the Therapeutics and Diagnostics Pipelines
Kaur, H., Bruno, J. G., Kumar, A., & Sharma, T. K. (2018) · Theranostics · doi:10.7150/thno.25958 · Cited by 366
Stone, C. A., Liu, Y., Relling, M. V., Krantz, M. S., Pratt, A. L., Abreo, A., Hemler, J. A., & Phillips, E. J. (2019) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2018.12.003 · Cited by 351
Yang, W., Wang, L., Mettenbrink, E. M., DeAngelis, P. L., & Wilhelm, S. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-032320-110338 · Cited by 327
From the RNA world to the clinic
Sullenger, B. A., & Nair, S. (2016) · Science · doi:10.1126/science.aad8709 · Cited by 274
Self-citationEngineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Waheed, S., Li, Z., Zhang, F., Chiarini, A., Armato, U., & Wu, J. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01605-4 · Cited by 259
Allergic reactions and anaphylaxis to LNP-based COVID-19 vaccines
Moghimi, S. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.01.030 · Cited by 150
Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
Mercier, M.-C., Dontenwill, M., & Choulier, L. (2017) · Cancers · doi:10.3390/cancers9060069 · Cited by 113
POxylation as an alternative stealth coating for biomedical applications
Bludau, H., Czapar, A. E., Pitek, A. S., Shukla, S., Jordan, R., & Steinmetz, N. F. (2017) · European Polymer Journal · doi:10.1016/j.eurpolymj.2016.10.041 · Cited by 112
Sun, Q., Yang, W., Song, Z., Lu, H., Shang, W., Li, H., Yang, Z., Gao, W., Li, Y., Xu, Y., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c11988 · Cited by 6
Metadata
- Authors
- Ganson, N. J., Povsic, T. J., Sullenger, B. A., Alexander, J. H., Zelenkofske, S. L., Sailstad, J. M., Rusconi, C. P., & Hershfield, M. S.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 137
- Issue
- 5
- Pages
- 1610-1613.e7
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2194343859
- Cited by
- 273
- References
- 14
- FWCI
- 15.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.